This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eisai Inc. ( Eisai Co., Ltd. )
ClinicalTrials.gov Identifier:
NCT00540670
First received: October 4, 2007
Last updated: May 9, 2013
Last verified: February 2010
October 4, 2007
May 9, 2013
October 2007
March 2009   (Final data collection date for primary outcome measure)
Safety and tolerability: Adverse events, bleeding events, clinical laboratory tests, Coagulation tests, vital signs and 12-lead ECG [ Time Frame: 6 months ]
Safety, tolerability.
Complete list of historical versions of study NCT00540670 on ClinicalTrials.gov Archive Site
Major cardiac adverse events, biomarkers, platelet aggregation inhibition, plasma concentration. [ Time Frame: 6 months ]
Major cardiac adverse events, biomarkers, platelet aggregation inhibition, plasma concentration.
Not Provided
Not Provided
 
A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease
A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease
The purpose of this study is to assess the safety and tolerability of E5555 in Japanese subjects with coronary artery disease.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Coronary Artery Disease
  • Drug: E5555 50 mg
    E5555 50 mg (tablet) taken orally, once a day.
  • Drug: E5555 100 mg
    E5555 100 mg (tablet) taken orally, once a day.
  • Drug: E5555 200 mg
    E5555 200 mg (tablet) taken orally, once a day.
  • Drug: Placebo
    Placebo (tablet) taken orally, once a day.
  • Experimental: 1
    Intervention: Drug: E5555 50 mg
  • Experimental: 2
    Intervention: Drug: E5555 100 mg
  • Experimental: 3
    Intervention: Drug: E5555 200 mg
  • Placebo Comparator: 4
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
240
Not Provided
March 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. 45 - 80 years old (at time of informed consent).
  2. Male or female (females of childbearing potential must use contraception).
  3. Confirmed coronary artery disease.
  4. All subjects must be receiving aspirin (75 - 325 mg).

Exclusion Criteria:

  1. Unwilling or unable to provide informed consent.
  2. History of acquired or congenital bleeding disorder, coagulopathy, or platelet disorder.
  3. Recent trauma or major surgery.
  4. Evidence of active pathological bleeding or history of bleeding such as gastrointestinal or genitourinary, unless the cause has been definitely corrected.
  5. History of intracranial bleeding or history of hemorrhagic retinopathy.
  6. New York Heart Association class III or IV congestive heart failure.
  7. Pregnant or lactating women.
Sexes Eligible for Study: All
45 Years to 80 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
 
NCT00540670
E5555-J081-206
Not Provided
Not Provided
Not Provided
Eisai Inc. ( Eisai Co., Ltd. )
Eisai Co., Ltd.
Not Provided
Study Director: Masaru Takeuchi New Product Development, Clinical Research Center, Eisai Co., Ltd.
Eisai Inc.
February 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP